Intravirion targeting of a functional anti-human immunodeficiency virus ribozyme directed to pol

Virology

Volumn 267, Issue 2, 2000, Pages 174-184

  Giordano, Vincenzo ^a   Jin, Dong Yan ^a   Rekosh, David ^b   Jeang, Kuan Teh ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOZYME;

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRION; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; FORMICIDAE; HIV 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034652541     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.0112     Document Type: Article

References (43)

1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J. Virol. 59:1986;284-291.
2. Akhtar S., Rossi J. J. Anti-HIV therapy with antisense oligonucleotides and ribozymes: Realistic approaches or expensive myths. J. Antimicrob. Chemiother. 38:1996;159-165.
3. Berkhout B., Silverman R., Jeang K.-T. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell. 53:1989;273-282.
4. Cech T. R. The chemistry of self-splicing RNA and RNA enzymes. Science. 236:1987;1532-1539.
5. Cech T. R. The efficiency and versatility of catalytic RNA: Implications for an RNA world. Gene. 135:1993;33-36.
6. Chesebro B., Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62:1988;3779-3788.
7. Coffin J. M. HIV population dynamics in vivo: Implication for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
8. Dimitrov D. S., Willey R. L., Sato H., Chang L. J., Blumenthal R., Martin M. A. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67:1993;2182-2190.
9. Dropulic B., Jeang K. T. Gene therapy for human immunodeficiency virus infection: Genetic antiviral strategies and targets for intervention. Hum. Gene Ther. 5:1994a;927-939.
10. Dropulic B., Jeang K. T. Intracellular susceptibility to ribozymes in a tethered substrate ribozyme provirus model is not predicted by secondary structures of human immunodeficiency virus type 1 RNAs in vitro. Antisense Res. Dev. 4:1994b;217-221.
11. Dropulic B., Lin N. H., Martin M. A., Jeang K. T. Functional characterization of a U5 ribozyme: Intracellular suppression of human immunodeficiency virus type 1 expression. J. Virol. 66:1992;1432-1441.
12. Dropulic B., Smith S. M., Jeang K. T. Activation and inactivation of gene expression using RNA sequences. Adv. Pharmacol. 30:1994;247-270.
13. Finzi D., Hermankova M., Pierson T., Carruth L. M., Buck C., Chaisson R. E., Quinn T. C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D. D., Richman D. D., Siliciano R. F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
14. + hematopoietic stem cells of HIV-infected individuals. Hum. Gene Ther. 8:1997;2229-2238.
15. Graham R. L., Van der Eb J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52:1973;456-467.
16. James H. A., Gibson I. The therapeutic potential of ribozymes. Blood. 91:1998;371-382.
17. Hammarskjöld M.-L., Wang S.-C., Klein G. High-level expression of the Epstein-Barr virus EBNA1 protein in CV1 cells and human lymphoid cells using a SV40 late replacement vector. Gene. 43:1986;41-50.
18. Haseloff J., Gerlach W. L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (Lond). 334:1988;585-591.
19. Ho A. D., Li X., Lane T. A., Yu M., Law P., Wong-Staal F. Stem cells as vehicle for gene therapy: Novel strategy for HIV infection. Stem Cells. 13:1995;100-105.
20. Homann M., Tzortzakaki S., Rittner K., Sczakiel G., Tabler M. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Res. 21:1993;2809-2814.
21. Kashani-Sabet M., Funato T., Florenes V. A., Fodstad O., Scanlon K. J. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 54:1994;900-902.
22. Kashani-Sabet M., Funato T., Tone T., Jiao L., Wang W., Yoshida E., Kashfinn B. I., Shitara T., Wu A. M., Moreno J. G., Traweek S. T., Ahlering T. E., Scanlon K. J. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. Dev. 2:1992;3-15.
23. Kiernan R. E., Ono A., Englund G., Freed E. O. Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J. Virol. 72:1998;4116-4126.
24. Kimpton J., Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:1992;2232-2239.
25. + donors: Prelude to a ribozyme gene therapy trial. Gene Ther. 3:1996;599-606.
26. Lisziewicz J., Sun D., Smythe J., Lusso P., Lori F., Louie A., Markham P., Rossi J., Reitz M., Gallo R. C. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc. Natl. Acad. Sci. USA. 90:1993;8000-8004.
27. Liu J., Woffendin C., Yang Z. Y., Nabel G. J. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Gene Ther. 1:1994;32-37.
28. Marasco W. A., Haseltine W. A., Chen S. Y. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. USA. 90:1993;7889-7893.
29. Piatak M. Jr., Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 259:1993;1749-1754.
30. Rizvi T. A., Panginabin T. Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus 1 particles. J. Virol. 67:1993;2681-2688.
31. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 239:1988;487-491.
32. Sarver N., Cantin E. M., Chang P. S., Zaia J. A., Ladne P. A., Stephens D. A., Rossi J. J. Ribozymes as potential anti-HIV-1 therapeutic agents. Science. 247:1990;1222-1225.
33. Smith S. M., Maldarelli F., Jeang K. T. Efficient expression by an alphavirus replicon of a functional ribozyme targeted to human immunodeficiency virus type 1. J. Virol. 71:1997;9713-9721.
34. Srinivasakumar N., Chazal N., Helga-Maria C., Prasad S., Hammarskjöld M.-L., Rekosh D. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J. Virol. 71:1997;5841-5848.
35. Stevenson M., Meier C., Mann A. M., Chapman N., Wasiak A. Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: Mechanism for persistence in AIDS. Cell. 53:1988;483-496.
36. Sullenger B. A. Colocalizing ribozymes with substrate RNAs to increase their efficicacy as gene inhibitors. Appl. Biochem. BioTechniques. 54:1995;57-61.
37. Sullenger B. A., Cech T. R. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science. 262:1993;1566-1569.
38. Symons R. H. Small catalytic RNAs. Annu. Rev. Biochem. 61:1992;641-671.
39. Wang S., Dolnick B. J. Quantitative evaluation of intracellular sense: Antisense RNA hybrid duplexes. Nucleic Acids Res. 21:1993;4383-4391.
40. Wong-Staal F., Poeschla E. M., Looney D. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum. Gene Ther. 9:1998;2407-2425.
41. Xing Z., Mahadeviah S., Whitton J. L. Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus. Antisense Res. Dev. 5:1995;203-212.
42. Yu M., Leavitt M. C., Maruyama M., Yamada O., Young D., Ho A. D., Wong-Staal F. Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 92:1995;699-703.
43. Zhou C., Bahner I., Rossi J. J., Kohn D. B. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: Comparison of RNA levels and viral inhibition. Antisense Nucleic Acid Drug Dev. 6:1996;17-24.